Genentech has reached a memorandum of understanding with JHL Biotech in its civil lawsuit related to the theft of Genentech’s trade secrets.
Genentech has reached a memorandum of understanding with JHL Biotech in its civil lawsuit related to the theft of Genentech’s trade secrets.
According to Genentech, the formal settlement, which remains to be executed, requires JHL to stop developing its biosimilars referencing Genentech’s products: rituximab (Rituxan), dornase alfa (Pulmozyme), trastuzumab (Herceptin), and bevacizumab (Avastin). JHL will also be required to destroy all cell lines and cell banks that are associated with these products, and the biosimilar developer must cease using or sharing any of Genentech’s confidential information. Several of the proposed biosimilars had already entered phase 3 development.
The agreement stems from allegations that Xanthe Lam, formerly employed as a scientist at the Roche Holding AG unit from 1986 until 2017, downloaded, collected, and transferred proprietary information to her husband, Allen Lam, and others at the China-based JHL. She also allegedly secretly consulted for JHL while still employed at Genentech.
In its civil complaint, Genentech pointed to the existence of documentary evidence, “including emails, text messages, Skype logs, and audit records…as well as admissions from [2] of the named defendants,” all of which “make clear that former Genentech employees and others at JHL conspired to give JHL an illegal and corrupt advantage in the biotechnology industry.” The complaint includes a screenshot from Xanthe Lam’s Genentech-issued computer, which shows a folder titled “JHL” that contained subfolders, 4 of which were named for Genentech medicines for which JHL was in the process of developing biosimilars.
Sean Johnston, senior vice president, general counsel, and chief compliance officer of Genentech, said in a statement concerning the agreement, "we're pleased to have secured the return of our property and the prevention of any further dissemination and illegal use. The agreement points to the significance of defending and protecting one's intellectual property rights, trade secrets and other confidential and proprietary information.”
Johnson added, “Leveraging trade secrets and confidential and proprietary information from an employer or a competitor to create an unfair and illegal competitive advantage is a serious crime. Dishonest and illegal actions such as these threaten scientific innovation, obstruct fair competition, and undermine the hard work of our employees and people throughout the industry who act with integrity and in the best interests of patients every day.”
JHL’s executive chairman and chief executive officer, James Huang, said in a statement that “after careful consideration, we determined the settlement provides the best path forward for the company to focus exclusively on delivering high-quality and affordable biosimilar medicines to patients in need. It also removes the costs and uncertainty associated with protracted litigation.” He added that JHL will be able to continue to develop “the remainder, and majority” of its biosimilar pipeline, which includes omalizumab, pertuzumab, denosumab, ipilimumab, ustekinumab, and ramucirumab.
The trade secrets theft is also the subject of a criminal case, and Genentech continues to pursue a civil lawsuit against the individuals involved in the matter. A Genentech representative told The Center for Biosimilars® in an email that the settlement reached does not impact the government’s criminal case, and Genentech is currently on hold with its suit regarding the individual defendants until the criminal case has been resolved. The case is scheduled for trial in April 2020.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).